Breast Fat Grafting vs SVF-assisted Fat Grafting
아래 사실은 모두 두 엔티티 페이지와 그 출처에서 가져온 것입니다. 양쪽이 함께 기록한 항목을 먼저 대조하고, 나머지는 나란히 보여 줍니다.
의료
Breast Fat GraftingBreast fat grafting (fat transfer breast augmentation) uses the patient's own liposuctioned fat to modestly enlarge or reshape the breast without an implant.갱신 2026년 9월 20일의료
SVF-assisted Fat GraftingSVF-assisted fat grafting (a form of cell-assisted lipotransfer) enriches the fat graft with stromal vascular fraction isolated from part of the harvested fat, with the aim of improving graft survival.갱신 2026년 9월 21일공통 항목
양쪽 모두 기록된 항목 1개| 항목 | Breast Fat Grafting | SVF-assisted Fat Grafting |
|---|---|---|
| US regulatory status | Following FDA guidance issued in November 2017, autologous fat grafts do not require premarket approval; stromal vascular fraction products receive closer review | Collagenase digestion to isolate SVF falls outside 'minimal manipulation'; non-enzymatic mechanical point-of-care methods are proposed as possible alternatives |
각각의 사실
둘 중 한쪽에만 기록된 검증된 사실입니다.
Breast Fat Grafting
DefinitionFat is taken by liposuction from other parts of the body and injected to enlarge the breasts
Typical donor sitesUsually the abdomen or flanks, though fat can be taken from almost anywhere (surgeon quoted by ASPS)
Typical size increaseSurgeon quoted by ASPS: ideal candidate wants half a cup to one cup; a larger increase may take two to three procedures
Listed risksCysts, infection, microcalcification, death of fat cells (necrosis), and some transferred fat leaving the breast area
Pre-expansion optionSurgeons may recommend an external tissue expansion system in the weeks before surgery
Pooled volume retention54% (95% CI 48.5–59.5%) across 25 studies, follow-up 3–36 months
Retention by fat preparation methodCentrifugation 51.5% vs sedimentation 38.7% pooled retention
Oncologic safety evidenceMeta-analysis of 15 studies (8,541 participants): no difference in overall survival, disease-free survival or local recurrence between patients who had fat grafting after breast cancer surgery and controls
1987 professional positionASPRS (predecessor of ASPS) condemned autologous fat injection for breast augmentation over concerns about cancer detection
2009 ASPS Fat Graft Task ForceConcluded that the literature then available showed no association between fat grafting and higher rates of malignancy
Relevant FDA guidanceSame Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception
Suitable forPeople wanting a relatively small increase in breast size who have enough donor fat (ASPS)
SessionsMore than one session may be needed because part of the graft is resorbed
Imaging noteFat necrosis, cysts and calcifications can appear on mammograms and must be interpreted by a radiologist
SVF-assisted Fat Grafting
First clinical descriptionYoshimura K et al., 'Cell-assisted lipotransfer for cosmetic breast augmentation', Aesthetic Plast Surg 2008;32(1):48–55; 40 women, maximum follow-up 42 months
Original procedureAbout half of the aspirated fat is processed to isolate fresh SVF, which is recombined with the other half before injection; the fat acts as a living scaffold
Pooled fat survival (2026 meta-analysis)72.78% with enrichment vs 45.28% conventional (SMD 2.44; 95% CI 1.00–3.88); 15 studies, 634 patients; heterogeneity I² = 97.19%
Efficacy by siteFace showed a significant benefit (SMD 2.95); breast reconstruction showed no significant advantage (SMD 0.47); no benefit with water-assisted lipotransfer harvesting
Methodological qualityAbout 62% of included studies rated weak overall; mean follow-up 16.2 months, too short for oncologic conclusions
Comparative study without benefitPeltoniemi et al. 2013 (JPRAS 66:1494–1503): 18 women, MRI at 6 months; graft survival 50% with Celution SVF enrichment vs 54% without, difference not significant
Breast-surgery evidence base11 studies, 336 patients, follow-up 6–42 months; 8 of 11 studies had no control group; only one used a validated patient-reported outcome measure (BREAST-Q)
Reported complications (breast)Calcifications were the most frequently reported complication; none reported as malignant
Preclinical and early clinical findings16 of 18 preclinical studies showed significantly improved retention (1.19- to 4.14-fold); 6 of 7 clinical studies favored CAL; evidence judged low quality
Applicable US FDA guidanceFinal guidance 'Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use', July 2020 (supersedes November 2017 version)
Also calledCell-assisted lipotransfer (CAL)
EvidenceA 2024 systematic review assessed the efficacy of cell-assisted lipotransfer; a 2021 study compared CAL with PRP-assisted lipotransfer
Proposed mechanismStromal cells may support angiogenesis and graft survival (hypothesis under study)